RDS has raised €14 million in a Series A funding round to expedite the commercialization and industrialization of its MultiSense® connected patient monitoring patch in France and Europe.

Target Information

RDS, a French medical technology company, has successfully raised €14 million in a Series A funding round. The primary investor, SPI (Sociétés de Projets Industriels), managed on behalf of the state by Bpifrance, along with Critical Path Ventures and several historical investors, supported this initiative. The funds will be utilized to accelerate the commercialization of MultiSense®, a connected patient monitoring patch, across France and Europe, while also enhancing production capabilities in France.

MultiSense® is a Class IIa CE-marked medical telemonitoring device that provides healthcare professionals with a comprehensive and highly accurate solution for continuously monitoring key physiological parameters of patients both in hospitals and at home. This clinically validated technology is currently being implemented in approximately 15 hospitals across France, Belgium, and Germany. Since this year, it has also been featured by major hospital purchasing centers like RESAH and UNIHA.

Industry Overview in France

The global vital signs monitoring market is projected to reach $15 billion by 2025, with an expected average annual growth rate of 15% until 2030. This trend signifies a shift towards accommodating patients at home, driven by the need to reduce hos